Apoptosis and cancer
PRINCIPAL INVESTIGATORS
- Avelina Tortosa Moreno
- Pepita Gimenez Bonafe
- Gabriel Pons Irazazabal
POSTDOCTORAL RESEARCHERS
- Ismael Sanchez Vera
SCIENTIFIC SUPPORT
- Ana Maria Cosialls Castel
- Josefina Martinez Soler
- Santiago Ambrosio Viale
Cancer
Oncobell
Scientific production
7
PAPERS
Average IF: 5,2
5
LED PAPERS
Average IF: 3,8
1 PUBLICATION IN FIRST DECILE
3 PUBLICATIONS IN FIRST QUARTILE
7 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Espinosa Sotelo,R;Fuste,NP;Penuelas Haro,I;Alay,A;Pons,G;Almodovar,X;Albaladejo,J et al, Dissecting the role of the NADPH oxidase NOX4 in TGF-beta signaling in hepatocellular carcinoma, Redox Biol., 2023;65102818-102818, doi:10.1016/j.redox.2023.102818
- Pedrosa,L;Bedia,C;Diao,DL;Mosteiro,A;Ferres,A;Stanzani,E;Martinez Soler,F et al, Preclinical Studies with Glioblastoma Brain Organoid Co-Cultures Show Efficient 5-ALA Photodynamic Therapy, Cells, 2023;12(8):doi:10.3390/cells12081125
- Sánchez Vera,I;Saura Esteller,J;Núñez Vázquez,S;Cosialls,AM;Ghashghaei,O;Lavilla,R;Pons,G et al, The prohibitin-binding compound fluorizoline induces the pro-inflammatory cytokines interleukin-8 and interleukin-6 through the activation of JNK and p38 MAP kinases, Biochem. Pharmacol., 2023;218115860-115860, doi:10.1016/j.bcp.2023.115860
- Sanchez Vera,I;Nunez Vazquez,S;Saura Esteller,J;Cosialls,AM;Heib,J;Rodriguez,PN;Ghashghaei,O et al, The Prohibitin-Binding Compound Fluorizoline Activates the Integrated Stress Response through the eIF2 alpha Kinase HRI, Int. J. Mol. Sci., 2023;24(9):doi:10.3390/ijms24098064
- Cabrero,EL;Robledo,RT;Cuñado,AC;Sardelli,DG;López,CH;Formatger,DG;Perez,LL et al, Risk factors of catheter- associated bloodstream infection: Systematic review and meta-analysis, PLoS One, 2023;18(3):doi:10.1371/journal.pone.0282290
Research highlights
PROJECTS
1 Granted competitive project
1 Ongoing competitive project
NETWORKS
AGAUR SGR GRC
APORED
Selected projects
- FIS22046. Desarrollo de estrategias terapéuticas para disminuir la resistencia a tratamientos convencionales en cáncer de pulmón. Instituto de Salud Carlos III (ISCIII). Budget: 141.570€. 2023-2025. PI: Soto Cerrato, Vanessa.